Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03330405 · ClinicalTrials.gov registry record · Phase 1
Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 223
- Enrollment target
NCT03330405: Clinical Trial Phase 1 study, sponsored by Pfizer.
NCT03330405 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 223 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (272% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03330405, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 223 participants
- Enrollment target
Study Summary
Avelumab in combination with talazoparib will be investigated in patients with locally advanced (primary or recurrent) or metastatic solid tumors, including non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), hormone receptor positive (HR+) breast cancer, recurrent platinum sensitive ovarian cancer, urothelial cancer (UC), and castration resistant prostate cancer (CRPC).
Primary Outcome
DLTs=occurrence of any of the following AEs attributable to any study treatment in Cycle 1:Hematologic: grade(G)4 neutropenia lasting \>5 days (absolute neutrophil count \[ANC\]\< 0.5\*10\^9/L); febrile neutropenia; neutropenic infection (ANC\<1.0\*10\^9/L, and G\>3 infection); G\>=3 thrombocytopenia (platelet count \[PC\] \<50.0\*10\^9/L) with bleeding; G4 thrombocytopenia (PC\<25.0\*10\^9/L); G4 anemia (life-threatening; urgent intervention indicated). Non-hematologic: G\>=3 toxicities unless
Interventions
- DRUG Avelumab Phase 1b
- DRUG Talazoparib Phase 1b
- DRUG Avelumab Phase 2
- DRUG Talazoparib Phase 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 223 participants |
| Start Date | 2017-10-19 |
| Est. Completion | 2023-01-04 |
| Phase | Phase 1 |
Why NCT03330405 stopped before completion
NCT03330405 is an interventional study that assigns participants to a tested intervention. The registered 223 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (272% higher).
The record links to 0 conditions, and to 4 interventions - of which Avelumab Phase 1b is the first listed.
NCT03330405 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03330405 about?
NCT03330405 is a clinical study titled "Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors". Avelumab in combination with talazoparib will be investigated in patients with locally advanced (primary or recurrent) or metastatic solid tumors, including non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), hormone receptor positive (HR+) breast cancer, recurrent platinum sen...
What is the current status of trial NCT03330405?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 223 participants. The study started on 2017-10-19. Estimated completion is 2023-01-04.
What interventions are being tested in trial NCT03330405?
The interventions under investigation include: Avelumab Phase 1b (DRUG), Talazoparib Phase 1b (DRUG), Avelumab Phase 2 (DRUG), Talazoparib Phase 2 (DRUG).
Who is sponsoring clinical trial NCT03330405?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03330405's enrollment target sits among peer trials
223 228th of 2000 higher than 1,772 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06640803 · 223 participants · NA
Sacramento Clinical High Risk for Psychosis Stepped-Care Program
- NCT07175285 · 223 participants
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
- NCT07205718 · 223 participants · Phase 1
A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
- NCT02706561 · 224 participants · NA
Helping Men Adhere to Sexual Rehabilitation Following Prostate Cancer Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI